THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures

Similar documents
Smokefree Policies in Europe: Are we there yet?

UK bowel cancer care outcomes: A comparison with Europe

Overview of drug-induced deaths in Europe - What does the data tell us?

Estimating Smoking Related Cause of Death: a Cohort Approach Based on Lung Cancer Mortality in six European Countries

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 SERBIA

Cross Border Genetic Testing for Rare Diseases

The health economic landscape of cancer in Europe

The cancer burden in the European Union and the European Region: the current situation and a way forward

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

Underage drinking in Europe

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

Where we stand in EFORT

Prof. Dr. Gabor Ternak

Table 9.1 Summary information for stomach cancer in Ireland,

Current levels and recent trends in health inequalities in the EU: Updates from the EU Report

Rheumatoid Arthritis Disease Burden and Access to Treatment

DECLARATION OF CONFLICT OF INTEREST. None

Monthly measles and rubella monitoring report

Primary and secondary prevention of sudden cardiac death in emerging economies

HIGH BLOOD PRESSURE. How can we do better?

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Maximising effectiveness of healthcare spend a thought starter

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

The Risk of Alcohol in Europe. Bridging the Gap June 2004

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

European status report on alcohol and health Leadership, awareness and commitment

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Alcohol in Europe and Brief Intervention. Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

Cost of Disorders of the Brain in Europe Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21,

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

European Partnership for Screening

European Collaboration on Dementia. Luxembourg, 13 December 2006

Engagement in language assessment / Regions of Europe

31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million

European Community Pharmacy: a reference in Public Health

Project Meeting Prague

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

The accident injuries situation

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

Table 7.1 Summary information for lung cancer in Ireland,

What can the NHS do to reduce premature mortality? Professor Sir Mike Richards NHS Health Check National Learning Event April 2013

Table 6.1 Summary information for colorectal cancer in Ireland,

Alcohol Prevention Day

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

Outcome of proficiency test on EIA serology

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

European Status report on Alcohol and Health

Cardiovascular Disease and Diabetes Policies for Better Health and Quality of Care

Alcohol-related harm in Europe and the WHO policy response

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

Extrapolation and potential impact of IPHS deployment in Europe

LEBANON. WCPT COUNTRY PROFILE December 2018

11 Melanoma of the skin

Present and potential perspectives for information on alcohol use in the EU

IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President

DENMARK. WCPT COUNTRY PROFILE December 2018

CNAPA Meeting Luxembourg September 2016

Screening for Cervical Cancer in Europe

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

The Identification of Food Safety Priorities using the Delphi Technique

Getting Serious About CVD Prevention What does this mean for Primary Care?

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

GERMANY. WCPT COUNTRY PROFILE December 2018

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Perspectives for information on alcohol use in the EU

EFSA s activities on data collection (Art. 33) and proposal for a new initiative (EUMENU) H. Deluyker Director

New trends in harm reduction in Europe: progress made challenges ahead

COMMISSION OF THE EUROPEAN COMMUNITIES

Prof Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT

Q1 What age are you?

Correction to: The education gradient in cancer screening participation: a consistent phenomenon across Europe?

real-time AQ data 2007 and plans for 2008

CHRODIS Kick-off. Communication and Dissemination. Cristina Chiotan / Anna Gallinat Public Health Coordinator / Communications Assistant

Models of preventive care in clinical practice to achieve 25 by 25

The burden caused by alcohol

The Economics of Tobacco Control and Tobacco Taxation: Challenges & Opportunities for a Tobacco Free Turkey

Nutrient profiles for foods bearing claims

National Institute on Alcohol Abuse and Alcoholism. Environmental Approaches

Where do EU Contries set the limit for low risk drinking.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Transcription:

THE CVD CHALLENGE IN NORTHERN IRELAND Together we can save lives and reduce NHS pressures

The challenge of CVD continues today. Around 225,000 people in Northern Ireland live with the burden of cardiovascular disease (CVD). Thousands more have undetected medical risk factors. CVD remains one of the biggest causes of death and disability in Northern Ireland, costing the NHS hundreds of millions of pounds each year. And despite significant successes in reducing CVD mortality, it remains a major contributor to premature death and health inequality. But it doesn t need to be like this. Working with health system leaders and governments, together we can tackle undetected hypertension, atrial fibrillation and high cholesterol, to reduce the burden of stroke and heart attack. We can improve the quality of care for patients with diagnosed conditions to reduce their risk. And we can improve patient outcomes by delivering innovative services. Together, let us change tomorrow.

After 40 years of falling premature CVD deaths, progress has slowed Under-75 age-standardised CVD death rate per 100,000 600 500 400 300 200 100 Men Women Both 0 72 76 80 84 88 92 Year 96 00 04 08 12 16 Premature CVD death rates in Northern Ireland have fallen 83% over the last 40 years, largely thanks to BHF-funded research, advances in treating conditions like heart attack and stroke and the decline in smoking, as well as lifestyle changes. But progress has slowed since 2011. The reasons are unclear. And CVD remains a significant cause of death in Northern Ireland. We must do more. 19% of all premature deaths in Northern Ireland are caused by CVD. That s 1,100 premature CVD deaths in Northern Ireland each year Data source: BHF CVD Statistics Compendium, 2018

We are living longer, but with more long-term conditions By 2025, the number of people living with one or more serious long-term conditions in the UK will increase by nearly one million 2015 2025 0 8.2 million 9.1 million 2 4 6 8 10 People living with long-term condition(s) in millions In Northern Ireland today, 225,000 people live with CVD. This makes up a significant proportion of all long-term conditions (LTCs). At least 16,500 people have heart failure. What s more, CVD risk increases with age: almost 8% of people in their 60s are diagnosed with coronary heart disease, for instance. And many other common LTCs increase the risk of developing CVD. By 2030, the population in Northern Ireland aged 65-84 will rise by 37% and those over 85 by 76%. We must plan for the future. Data source: Royal College of General Practitioners (2016). Responding to the needs of patients with multimorbidity: A vision for general practice

CVD healthcare costs Northern Ireland hundreds of millions of pounds a year 412 million CVD healthcare costs estimate 600 million CVD economic cost estimate The direct and indirect costs of CVD to the NHS in Northern Ireland and the wider economy are significant. Meanwhile, Health and Social Care in Northern Ireland (HSCNI) needs to make efficiency savings of 1.9 billion per year by 2020/21 to avoid a significant rise in spending. We can bring down this cost. Data sources: BHF analysis of European Cardiovascular Disease Statistics 2017, EHN Hospital Information Branch, DHNI 2014/15

You re up to 30% more likely to die early from CVD depending on where you live CVD death rate for under-75s (age-standardised) Premature CVD death rate rises in line with deprivation 100 80 60 40 20 0 Derry & Strabane, most deprived 2 4 6 Lisburn & Castlereagh, least deprived 8 10 Rank of average deprivation by local authority (most to least) 12 CVD risk factors such as smoking, physical inactivity and obesity are more common in deprived areas of Northern Ireland. These increase the risk of hypertension, atrial fibrillation (AF) and high cholesterol. So the most deprived people in our society shoulder the greatest burden of death and disability from CVD. We must close this inequality gap. Data sources: Office for National Statistics 2017 and Northern Ireland Statistics and Research Agency 2017, data for 2014-16 The premature CVD death rate is 1.3 times higher in the most deprived area of Northern Ireland compared to the least. More information at bhf.org.uk/cvd-ni

We could perform better against other EU nations for premature CVD deaths Despite decades of success bringing down the premature CVD death rate, Northern Ireland still ranks lower than 15 other EU nations behind Slovenia, Cyprus and Malta. We can do better. Northern Ireland s premature CVD death rate is 45% more than France, which has the lowest rate among EU countries Together, we can make the difference. Turn over to find out how. Data source: Global Burden of Disease, 2015 France Spain Luxembourg Netherlands Italy Belgium Denmark Portugal Ireland England Sweden Cyprus Austria Malta Slovenia Northern Ireland Germany Wales Scotland Finland Greece Czech Republic Poland Croatia Slovakia Estonia Hungary Lithuania Latvia Romania Bulgaria 0 1000 2000 3000 4000 5000 6000 7000 Years of life lost from CVD per 100,000 (age-standardised)

Together, we can act to reduce this burden. Thousands of people have undetected medical risk factors that increase their chance of developing CVD. We can diagnose and treat them earlier. Many with diagnosed risk factors receive sub-optimal treatment. We can improve care. Patients experience varying standards of care and outcomes depending on where they live. We can innovate to improve patient outcomes.

Thousands could benefit from earlier risk factor detection and treatment Hypertension is implicated in half of all strokes and heart attacks People with AF are five times more likely to have a stroke Raised cholesterol increases the risk of heart attack and stroke We already have effective treatments available Every 10mmHg drop in systolic blood pressure reduces the risk of strokes and heart attacks by 20%. Anticoagulation for AF prevents 66% of related strokes. Every 1mmol/l fall in LDL cholesterol from statin treatment reduces yearly risk of heart attack and stroke by 25%. The problem is that significant variation in detection rate and treatment remains.

Better risk factor management could avoid hundreds of CVD events The missed opportunities 42,900 (17%)* Adults with diagnosed hypertension not treated to guidelines 66,900 (51%) Estimated number of adults with 10-year CVD risk above 20% not treated with statins The potential Over 3 years, optimally treating adults with diagnosed hypertension can avoid: 380 strokes 260 heart attacks And optimally treating high-risk AF patients can avoid: 210 strokes 2,600 (10%)* High-risk AF patients not anticoagulated * figures do not include QOF exception data so may not be comparable with other UK nations. For more information visit bhf.org.uk/cvd-ni BHF analysis based on The Size of the Prize in CVD Prevention, Public Health England 2017

It s time to think differently about CVD services The BHF has piloted and evaluated models of care that can avoid hospital admissions, improve patient outcomes and save the NHS millions of pounds a year. Now they need wider roll-out. Atrial fibrillation The challenge Around 210 strokes in Northern Ireland could be avoided over three years if everyone with AF was diagnosed and received appropriate anticoagulation therapy. The solution Arrhythmia Care Coordinators can help to enhance and optimise AF detection and management, reducing stroke incidence. Learn more at bhf.org.uk/acc Familial hypercholesterolaemia (FH) The challenge The inheritable gene mutation leads to abnormally high blood cholesterol levels, raising an otherwise healthy person s risk of dying from a heart attack in their 20s, 30s or 40s. The solution Cascade testing first-degree relatives of people with FH can help identify and treat at-risk family members. A BHF pilot has so far found over 1,400 cases and offered treatment to lower CVD risk. Learn more at bhf.org.uk/fhservice Hypertension A significant proportion of adults with hypertension remain undiagnosed. Of those who are, one in six are not treated to target. How can we do better? The BHF and partners in primary care, public health and the third sector came together to produce a resource that highlights these problems and offers solutions. Learn more at bhf.org.uk/bp-better What s next? Find out more about the challenge of CVD today and what the BHF is doing to change tomorrow. Visit bhf.org.uk/cvd-ni

For over 50 years our research has saved lives. We ve broken new ground, revolutionised treatments and transformed care. But heart and circulatory disease still kills one in four people in the UK. That s why we need you. With your support, your time, your donations, our research will beat heart disease for good. The BHF would like to thank the Institute of Applied Health Research at the University of Birmingham for its contribution to this publication. For full references visit bhf.org.uk/cvd-ni CBNI0318 BHF 2018, reg charity no 225971/SC039426